Tanvex Biopharma AI Stock Analysis
Want to see TW:6541 full AI Analyst Report?
Tanvex Biopharma (6541) AI Stock Analysis
Tanvex Biopharma
(TWSE:6541)
The score is weighed down primarily by weak financial performance—large ongoing losses, negative margins, and significant cash burn—despite strong revenue growth and a healthier leverage profile in 2025. Technical signals also remain bearish with the price below major moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend support.
Tanvex Biopharma (6541) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 432.45K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 207.37%
- EPS Growth
- 4.17%
- Country
- TW
- Employees
- 215
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Tanvex Biopharma Business Overview & Revenue Model
Company Description
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medici...
Tanvex Biopharma Financial Statement Overview
Summary
Despite sharp 2025 revenue growth (~78% vs. 2024) and improved leverage (debt-to-equity ~0.28), the business remains dominated by heavy operating and net losses, deteriorating margins (including negative gross margin), and significant ongoing cash burn. The improved capital structure helps, but weak profitability and negative operating/free cash flow materially constrain the score.
Income Statement
18Very NegativeBalance Sheet
47NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 657.56M | 400.97M | 34.68M | 61.41M | 22.40M | 5.41M |
| Gross Profit | -984.67M | -440.71M | 8.29M | 59.70M | -19.35M | 3.55M |
| EBITDA | -1.02B | -1.02B | -1.04B | -1.75B | -1.30B | -1.25B |
| Net Income | -1.47B | -1.50B | -1.38B | -2.14B | -1.64B | -1.54B |
Balance Sheet | ||||||
| Total Assets | 7.63B | 7.96B | 2.74B | 2.76B | 3.42B | 4.71B |
| Cash, Cash Equivalents and Short-Term Investments | 592.56M | 878.71M | 376.96M | 380.75M | 786.23M | 2.22B |
| Total Debt | 2.08B | 1.58B | 1.65B | 1.73B | 1.84B | 1.76B |
| Total Liabilities | 2.67B | 2.27B | 1.84B | 1.94B | 2.03B | 1.92B |
| Stockholders Equity | 4.97B | 5.69B | 893.31M | 821.11M | 1.39B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | -1.75B | -1.68B | -1.26B | -1.51B | -1.43B | -1.42B |
| Operating Cash Flow | -934.97M | -1.01B | -1.15B | -1.43B | -1.33B | -1.39B |
| Investing Cash Flow | -784.34M | 301.80M | -109.25M | -83.57M | -97.35M | -24.68M |
| Financing Cash Flow | 1.69B | 1.14B | 1.26B | 1.08B | -123.29M | 1.60B |
Tanvex Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:6541, the sentiment is Negative. The current price of 28.15 is below the 20-day moving average (MA) of 29.32, below the 50-day MA of 30.87, and below the 200-day MA of 39.33, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 65.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:6541.
Tanvex Biopharma Peers Comparison
Overall Rating
- TW:654143Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6541 | 43Neutral | TWD 7.47B | -5.03 | -26.61% | ― | 207.37% | 4.17% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6541 | Tanvex Biopharma | 28.15 | -27.55 | -49.46% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 08, 2026